Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | DPP4 | P27487 | 10/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PARG | Q86W56 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16845918 | 0.90 | HPGD (0.60) | CYP3A4DPP4OPRM1OPRK1KMT2A | |
| SCHEMBL28406812 | 0.85 | DPP4 (0.58) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL17036598 | 0.85 | DPP4 (0.58) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL8417573 | 0.84 | DPP4 (0.57) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL389683 | 0.84 | DPP4 (0.57) | CYP3A4DPP4OPRM1OPRK1KMT2A | |
| SCHEMBL16845920 | 0.81 | DPP4 (0.54) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL21253399 | 0.80 | DPP4 (0.56) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL7932462 | 0.79 | DPP4 (0.77) | DPP4OPRM1OPRK1KMT2AALDH1A1 | |
| SCHEMBL28406806 | 0.77 | DPP4 (0.51) | DPP4OPRM1OPRK1KMT2APARG | |
| SCHEMBL28077382 | 0.77 | DPP4 (0.75) | DPP4OPRM1OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2410855-B1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA LTD (IL) | 2016-06-01 | — | — | EP | disclosed |
| US-8841447-B2 | Process for the preparation of alogliptin | MAPI PHARMA LTD. (IL) | 2014-09-23 | — | — | US | disclosed |
| US-20120029000-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA LIMITED (IL) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029000-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | DPP7, DPP4, DPP8 | CYP3A4 233/4885DPP4 2/4885OPRM1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.